Fig. 5: MIR200CHG inhibits YB-1 ubiquitination and degradation. | npj Breast Cancer

Fig. 5: MIR200CHG inhibits YB-1 ubiquitination and degradation.

From: Long non-coding RNA MIR200CHG promotes breast cancer proliferation, invasion, and drug resistance by interacting with and stabilizing YB-1

Fig. 5

a qRT-PCR was used to detect the changes in the YB-1 mRNA when MIR200CHG was knocked down or overexpressed. b Western blotting was used to detect YB-1 expression when MIR200CHG was knocked down or overexpressed. c Western blotting was used to measure the expression of YB-1 in breast cancer cells following treatment with cycloheximide (CHX) after knockdown or overexpression of MIR200CHG. MCF7 cells were treated with 50 μg/mL CHX for 2 or 4 h. MDA-MB-231 cells were treated with 100 μg/mL CHX for 2, 4, or 6 h. d Western blotting was used to measure the expression of YB-1 in breast cancer cells that were treated with MG132 after knockdown or overexpression of MIR200CHG. Cells were treated with MG132 (25 μM) for 3 h. e, f Cell lysates of MCF7-sh and its negative control, or MDA-231-exp and its negative control were subjected to YB-1 immunoprecipitation, and then anti-Ub antibody was used to detect the levels of ubiquitinated YB-1 by western blotting. The cells were treated with MG132 (10 μM) for 24 h. Data in (b–f) are representative of at least two independent experiments.

Back to article page